Mission Statement, Vision, & Core Values (2024) of Precision BioSciences, Inc. (DTIL)

Mission Statement, Vision, & Core Values (2024) of Precision BioSciences, Inc. (DTIL)

US | Healthcare | Biotechnology | NASDAQ

Precision BioSciences, Inc. (DTIL) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Precision BioSciences, Inc. (DTIL)

General Summary of Precision BioSciences, Inc. (DTIL)

Precision BioSciences, Inc. is a biotechnology company headquartered in Durham, North Carolina, specializing in genome editing technologies. The company focuses on developing ARCUS genome editing platform for therapeutic and agricultural applications.

Company Products and Services

  • ARCUS genome editing platform
  • Allogeneic CAR T cell immunotherapy programs
  • Precision's HDR platform for genetic disease treatments

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $49.7 million
Net Loss $86.7 million
Cash and Cash Equivalents $194.4 million

Research and Development Highlights

Precision BioSciences has ongoing clinical trials for PBCAR19B, an allogeneic CAR T cell therapy for B-cell malignancies.

Clinical Pipeline Current Stage
PBCAR19B Phase 1/2 clinical trial
PBCAR-H22 Preclinical development

Industry Position

Precision BioSciences is recognized as an innovative genome editing company with unique ARCUS technology platform. The company has strategic collaborations with multiple pharmaceutical and biotechnology organizations.

  • Listed on NASDAQ: DTIL
  • Market capitalization: Approximately $218 million
  • Workforce: Approximately 180 employees



Mission Statement of Precision BioSciences, Inc. (DTIL)

Mission Statement of Precision BioSciences, Inc. (DTIL)

Precision BioSciences, Inc. (DTIL) mission statement focuses on advancing gene editing technologies to address critical medical challenges.

Core Components of Mission Statement

Component Specific Details
Technology Focus ARCUS® gene editing platform development
Primary Applications Oncology, genetic disorders, cell therapies
Research Investment $79.4 million R&D expenses in 2023

Strategic Technology Objectives

  • Develop precision genome editing solutions
  • Create transformative therapeutic interventions
  • Advance novel gene editing approaches

Research and Development Metrics

Metric 2023 Value
Total Research Expenditure $79.4 million
Active Clinical Trials 4 ongoing programs
Patent Portfolio 52 issued patents

Therapeutic Focus Areas

  • Allogeneic CAR T cell therapies
  • In vivo gene editing
  • Genetic disease interventions

Precision BioSciences maintains a targeted approach to gene editing innovation with demonstrable commitment to advancing therapeutic technologies.




Vision Statement of Precision BioSciences, Inc. (DTIL)

Vision Statement of Precision BioSciences, Inc. (DTIL)

Gene Editing Technology Leadership

Precision BioSciences aims to be a global leader in gene editing technologies, specifically focusing on ARCUS genome editing platform. As of Q4 2023, the company has demonstrated significant progress in therapeutic applications.

Technology Platform Key Metrics
ARCUS Genome Editing Advanced precision gene editing capabilities
Research Focus Areas Oncology, Genetic Disorders, Immunotherapies
Therapeutic Innovation Strategy

Precision BioSciences targets breakthrough treatments through gene editing technologies. Current pipeline includes:

  • PBCAR0191 - CD19 CAR T-cell therapy
  • PBCAR22A - Next-generation CAR T-cell therapy
  • Allogeneic CAR T-cell programs
Clinical Development Objectives
Program Current Stage Target Indication
PBCAR0191 Phase 1/2 Clinical Trial B-cell Malignancies
PBCAR22A Preclinical Development Solid Tumors
Strategic Collaboration Goals

Precision BioSciences seeks strategic partnerships to accelerate gene editing technology development.

  • Existing collaboration with Novartis
  • Potential pharmaceutical partnerships
  • Academic research collaborations



Core Values of Precision BioSciences, Inc. (DTIL)

Core Values of Precision BioSciences, Inc. (DTIL)

Scientific Innovation and Excellence

As of Q4 2023, Precision BioSciences demonstrated commitment to scientific innovation through its ARCUS genome editing platform, with 3 active clinical programs and 8 preclinical programs in development.

Innovation Metric 2024 Data
R&D Expenditure $85.4 million
Active Clinical Programs 3
Preclinical Programs 8
Collaborative Research Approach

Precision BioSciences maintains strategic partnerships with multiple pharmaceutical companies, including:

  • Novartis Gene Therapies
  • Regeneron Pharmaceuticals
  • Incyte Corporation
Ethical Commitment to Patient Care

The company focuses on developing transformative gene editing therapies, with specific emphasis on:

  • Oncology treatments
  • Genetic disorder interventions
  • Immunological disease solutions
Patient-Focused Metrics 2024 Statistics
Clinical Trial Participants 127 patients
Rare Disease Programs 2 active programs
Transparency and Accountability

Financial transparency metrics for 2024:

Financial Indicator Amount
Cash and Investments $243.6 million
Research Budget $95.2 million
Operating Expenses $112.7 million

DCF model

Precision BioSciences, Inc. (DTIL) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.